Commentary - EC final report: bark worse than bite?
This article was originally published in Scrip
On July 8th, 2009, the European Commission reported on its 18-month inquiry into competition in the pharmaceuticals sector. Bill Batchelor of Baker & McKenzie's Brussels antitrust practice describes some of the implications of the much-awaited report.
You may also be interested in...
A new pharmaceutical strategy is to be published later this year aimed at ensuring the availability and the supply of medicines.
Bill Batchelor highlights the far-reaching implications of the AstraZeneca judgment.
On 1 July 2010 the EU General Court handed down its judgement in the long-running saga of AstraZeneca's proton pump inhibitor anti-ulcer product Losec (omeprazole). Although dealing with events that happened almost two decades ago, the case – barring appeal – is set to cast a long shadow over the activities of patent and regulatory professionals.